A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-10 and is reviewed periodically as new material appears.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
is a surface integral. (Note that the concept that is here called "flux" is alternatively termed flux density in some literature, in which context "flux" denotes the surface integral of flux density. See the main article on Flux for details.)
=== Hospital requirements and staff training === Since the patient group receiving radioligand therapy is narrow, many health care providers are not equipped or eligible to administer radioligand therapy. PET imaging machines, a lead-shielded area, and trained professionals must be available.
The branch of medical science that deals with the study of incidence and distribution and control of a disease in a population. (NLM) The study of the patterns, causes, and control of disease in groups of people. (NCI) Equivalence trial
Sources: en.wikipedia.org
== Tactics within Rhodesia == In line with 'pseudo' doctrine, the role of the Selous Scout was to infiltrate the black population of Rhodesia and penetrate networks of insurgents. They were to then collect intelligence on the locations of insurgent forces and guide attacks on them. Where possible, Selous Scout teams would remain in place for lengthy periods. Selous Scout teams were also used in a 'hunter killer' role, in which they followed insurgent supply networks from contested areas within Rhodesia to neighbouring countries and killed any insurgents they located during the process. Selous Scout teams were usually successful in impersonating insurgents, even though their tradecraft was at times poor. The unit was more successful in penetrating ZANLA than ZIPRA, as the latter was better disciplined and had stronger command and control processes. To prevent the regular army or police from firing at Selous Scout teams while they were operating, authorities would declare "frozen areas", where all Army and Police units were ordered to temporarily cease all operations in, and withdraw from, without being told the actual rationale. Little information was provided to the Army units on the results of these operations or the intelligence that was collected. 'Freezing' areas generally proved operationally successful, but there were several occasions in which the security forces inadvertently attacked and killed Selous Scouts. The Rhodesian military established fireforce teams to exploit the intelligence collected by the Selous Scouts.
Selenium is a chemical element; it has symbol Se and atomic number 34. It has various physical appearances, including a brick-red powder, a vitreous black solid, and a grey metallic-looking form. It seldom occurs in this elemental state or as pure ore compounds in Earth's crust. Selenium (from σελήνη 'moon') was discovered in 1817 by Jöns Jacob Berzelius, who noted the similarity of the new element to the previously discovered tellurium (named for the Earth). Selenium is found in metal sulfide ores, where it substitutes for sulfur. Commercially, selenium is produced as a byproduct in the refining of these ores. Minerals that are pure selenide or selenate compounds are rare. The chief commercial uses for selenium today are glassmaking and pigments. Selenium is a semiconductor and is used in photocells. Applications in electronics, once important, have been mostly replaced with silicon semiconductor devices. Selenium is still used in a few types of DC power surge protectors and one type of fluorescent quantum dot. Although trace amounts of selenium are necessary for cellular function in many animals, including humans, both elemental selenium and (especially) selenium salts are toxic in even small doses, causing selenosis. Symptoms include (in decreasing order of frequency): diarrhea, fatigue, hair loss, joint pain, nail brittleness or discoloration, nausea, headache, tingling, vomiting, and fever.
Phase I trials, usually in healthy volunteers, determine safety and dosing. Phase II trials are used to get an initial reading of efficacy and further explore safety in small numbers of patients having the disease targeted by the NCE. Phase III trials are large, pivotal trials to determine safety and efficacy in sufficiently large numbers of patients with the targeted disease. If safety and efficacy are adequately proved, clinical testing may stop at this step and the NCE advances to the new drug application (NDA) stage. Phase IV trials are post-approval trials that are sometimes a condition attached by the FDA, also called post-market surveillance studies. The process of defining characteristics of the drug does not stop once an NCE is advanced into human clinical trials. In addition to the tests required to move a novel vaccine or antiviral drug into the clinic for the first time, manufacturers must ensure that any long-term or chronic toxicities are well-defined, including effects on systems not previously monitored (fertility, reproduction, immune system, among others). If a vaccine candidate or antiviral compound emerges from these tests with an acceptable toxicity and safety profile, and the manufacturer can further show it has the desired effect in clinical trials, then the NCE portfolio of evidence can be submitted for marketing approval in the various countries where the manufacturer plans to sell it. In the United States, this process is called a "new drug application" or NDA.
A lack of economy of size: as most fine chemicals are produced in quantities of less than a few 10 tons per year in multipurpose plants, there is little or no economy of size. The reactor trains of these plants are similar throughout the industry. Regardless of the size of the companies, their main constituents, the reaction vessels, have a median size of 4–6 m3 (140–210 cubic feet). Various products are made throughout a year in campaigns. Therefore, the unit cost per m3 per hour rarely varies with the size of the company. A dichotomy between ownership and management: the company's shares are listed on stock exchanges, and their performance is scrutinized by the financial community. Postponement of a single important shipment can affect a quarterly result. In the small and mid-sized companies, the owners are typically the major shareholders, often members of the same family. Their shares are not traded publicly and fluctuations in their financial performance are more easily coped with. Complicated business processes: flexibility and responsiveness are in jeopardy. Customer complaints, for instance, are difficult to resolve in a straightforward manner. A heterogeneous portfolio of small companies, accumulated over time through M&A activities. The key functions, such as production, R&D, and M&S, are located on different sites, often in different countries. Cohabitation with other units. A comprehensive list of about 1400 fine chemical companies (including traders) can be found in the "event catalogue" of the CPhI exhibition.
Sources: en.wikipedia.org
Sinosauropteryx was the first non-avian dinosaur to have its life colouration described by scientists based on physical evidence. Some fossils of Sinosauropteryx show an alternation of lighter and darker bands preserved on the tail. Chen and colleagues initially interpreted this banding pattern as an artifact of the splitting between the main slab and counter slab in which the original specimen was preserved. However, Longrich suggested in his 2002 presentation for the Society of Vertebrate Paleontology that these specimens actually preserve remnants of the colouration pattern the animal would have exhibited in life. He argued that the dark, banded areas on the tail were too evenly spaced to have been caused by random separation of the fossil slabs, and that they represent fossilized pigments present in the feathers. Additionally, rather than an artifact of preservation or decomposition, the presence of dark feathers along only the top of the body may also reflect the colour pattern in life, indicating that Sinosauropteryx prima was countershaded with dark colouration on its back and lighter colouration on its underside, with bands or stripes on the tail for camouflage. Longrich's conclusions were supported in a paper first published online in the journal Nature in January 2010. Fucheng Zhang and colleagues examined the fossilized feathers of several dinosaurs and early birds, and found evidence that they preserved melanosomes, the cell components that give the feathers of modern birds their colour.
The emergent long elimination timescale appears because not only is the intrinsic degradation time scale an order of magnitude longer than that of binding, but also because the endosomal antibody concentration is low due to high binding affinity. In particular, the analysis shows that clearance in the terminal phase is inherently nonlinear, with clearance,
=== Clinically isolated syndrome === The earliest clinical presentation of relapsing-remitting multiple sclerosis is the clinically isolated syndrome (CIS), that is, a single attack of a single symptom. During a CIS, there is a subacute attack suggestive of demyelination which should be included in the spectrum of MS phenotypes. Treatment with interferons after an initial attack decreases the risk of developing clinical definite MS.
The earliest efforts used methods similar to those used by Dayhoff, using large-scale matching of the protein database to generate a new log-odds matrix and the JTT (Jones-Taylor-Thornton) model. The rapid increases in compute power in the 21st century (reflecting factors such as Moore's law) made it feasible to estimate parameters for empirical models using maximum likelihood (e.g., the WAG and LG models) and other methods (e.g., the VT and PMB models). The IQ-Tree software package allows users to infer their own time reversible model using QMaker, or non-time-reversible using nQMaker. These methods produce both a tree and a best-fitting matrix. GTR is also available in IQ-Tree. The inference of custom models and GTR require a relatively large alignment due to the large number of parameters involved. As a consequence, a large number of empirical substitution models of protein evolution are currently available. These substitution models are derived from protein sequences of different taxonomic groups and protein families such as nuclear proteins, chloroplast proteins, mitochondrial proteins, and viral proteins, among others. A singular empirical model assume a constant set of amino acid frequencies over the entire evolutionary tree, which is often not the case over wide-spanning trees. The Bayesian CAT model was introduced in 2004. Maximum-likelihood version of it with 10–60 empirical profiles (C10–C60) were introduced in 2008. These methods are available in PhyML and IQ-TREE.
A familiar example of the opposite, a shear thinning fluid, or pseudoplastic fluid, is wall paint: The paint should flow readily off the brush when it is being applied to a surface but not drip excessively. Note that all thixotropic fluids are extremely shear thinning, but they are significantly time dependent, whereas the colloidal "shear thinning" fluids respond instantaneously to changes in shear rate. Thus, to avoid confusion, the latter classification is more clearly termed pseudoplastic. Another example of a shear thinning fluid is blood. This application is highly favoured within the body, as it allows the viscosity of blood to decrease with increased shear strain rate.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.